Illumina Unveils TruSight™ Oncology 500 v2 for Comprehensive Genomic Profiling

Tagomics Partners with Agilent Technologies to Revolutionize Multiomic Biomarker Discovery

Bio-Techne Partners with Leader Life Sciences to Expand in the GCC Region

Owkin and Proscia Partner to Revolutionize MSI Testing for Colorectal Cancer with AI-Powered Solutions

Telix Expands Theranostic Pipeline with FAP-Targeting Radiopharmaceuticals

Alamar Biosciences and The Michael J. Fox Foundation Partner to Advance Parkinson’s Disease Biomarker Discovery

Stilla Technologies Partners with Source BioScience to Advance Genomics in the UK and Ireland

Quell Therapeutics and AstraZeneca Advance CAR-Treg Therapy for Type 1 Diabetes

AbbVie’s ELAHERE® Approved in the EU for Platinum-Resistant Ovarian Cancer

AstraZeneca’s Tagrisso Recommended for Approval in EU for Unresectable EGFR-Mutated NSCLC

Foundation Medicine Receives FDA Approval for FoundationOne®Liquid CDx as a Companion Diagnostic for TEPMETKO® in NSCLC

Exact Sciences Partners with Carlos Ponce to Boost Colorectal Cancer Awareness in the Hispanic Community

Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

Home
/
update
/
details

Tagomics Partners with Agilent Technologies to Revolutionize Multiomic Biomarker Discovery

NextEdge Admin

21 Nov 2024

2 min 37 sec

Agilent Technologies,Multiomic,Biomarker Discovery

Tagomics Ltd., an innovative biomarker discovery and diagnostics company, has entered into a strategic co-marketing agreement with Agilent Technologies, a global leader in genomics tools. This partnership offers select customers exclusive access to a combined technology platform through a Technology Access Program hosted at Tagomics’ Cambridge service lab.

Tagomics’ Interlace™ multiomics platform employs a novel epigenetic profiling approach that enriches unmethylated DNA for analysis without altering its sequence. By integrating whole-genome or targeted sequencing with advanced bioinformatics and machine learning, Interlace provides a cost-effective, low-input, automatable workflow to analyze epigenetic, genetic, and fragmentomic features in a unified process.

Agilent Technologies brings its expertise in targeted genomic profiling with the SureSelect Library Preparation and Target Enrichment System. Combined with SureSelect Cancer Panels, this system detects a range of somatic variants, including SNVs, CNVs, indels, translocations, gene fusions, and critical immuno-oncology biomarkers like tumor mutational burden (TMB) and microsatellite instability (MSI).

The partnership integrates Agilent’s SureSelect XT HS2 technology into the Interlace workflow, offering seamless genomic and epigenomic analysis within a single platform. This collaboration enables researchers to gain comprehensive insights into disease mechanisms, paving the way for new diagnostic and therapeutic strategies.

“We’re excited to combine our Interlace platform with Agilent’s proven technologies to deliver deeper biological insights,” said Dr. Jack Kennefick, CEO of Tagomics. Ronda Allen, General Manager of Genomics at Agilent, added, “This partnership enhances our shared mission to advance genomic science and unlock new possibilities for our customers.”

The joint Technology Access Program allows select customers to experience these capabilities firsthand, driving innovation in biomarker discovery and disease understanding.